

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DEC 2020

(The figures have not been audited)

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current Year Quarter ended 31 Dec 2020 (Unaudited) RM'000	Preceding Year Corresponding Quarter 31 Dec 2019 (Unaudited) RM'000	Current Year To-Date 31 Dec 2020 (Unaudited) RM'000	Preceding Year Corresponding Period 31 Dec 2019 (Audited) RM'000
Revenue	5,865	5,116	18,075	18,849
Cost of sale	(4,366)	(3,013)	(11,953)	(12,043)
Gross profit	1,499	2,103	6,122	6,806
Other Operating Income	87	139	882	765
Administrative and distribution expenses	(2,072)	(1,789)	(5,805)	(6,375)
Other Operating Expenses	(375)	(1,059)	(1,678)	(1,754)
Share of net (loss)/ profit from an associate	17	(18)	(43)	(102)
Profit/(loss) before tax	(844)	(624)	(522)	(660)
Income tax expense	B5 (283)	(170)	(283)	(96)
Profit/(loss) after tax	(1,127)	(794)	(805)	(756)
Attributable to :				
Equity holders of the parent	(1,026)	(788)	(943)	(890)
Non-controlling Interest	(101)	(6)	138	134
	(1,127)	(794)	(805)	(756)
Earnings per share attributable to equity holders of parent :				
Basic (sen)	B13 (0.279)	(0.257)	(0.257)	(0.290)
Diluted (sen)	B13 (0.230)	(0.257)	(0.211)	(0.290)
EBITDA ⁽¹⁾	(344)	396	951	892

Note:-

⁽¹⁾ Profit before interest income, finance cost, tax, depreciation, amortisation and allowances.

(The unaudited Condensed Consolidated Income Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DEC 2020
(The figures have not been audited)

	Unaudited 31 Dec 2020 RM'000	Audited 31 Dec 2019 RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	11,019	11,463
Investment in an associated company	463	507
Intangible assets	182	56
Right-of-use assets	2,685	3,117
Goodwill	8	8
	<u>14,357</u>	<u>15,151</u>
Current Assets		
Inventories	1,816	1,662
Trade receivables	3,414	4,406
Other receivables	1,401	2,834
Contract Assets	4,296	5,210
Amount due from an associate	7,739	670
Amount due from directors	1	-
Tax recoverable	277	338
Other short term investments	31,340	2,494
Deposit, cash and bank balances	18,640	16,636
	<u>68,924</u>	<u>34,250</u>
TOTAL ASSETS	<u>83,281</u>	<u>49,401</u>
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the parent		
Share capital	65,585	31,089
Reserves	5,602	6,550
	<u>71,187</u>	<u>37,639</u>
Non-controlling interest	<u>1,385</u>	<u>1,197</u>
Total equity	<u>72,572</u>	<u>38,836</u>
Non-Current Liabilities		
Term Loan	B7 5,915	6,276
Lease liabilities	B7 292	337
Deferred taxation	-	2
	<u>6,207</u>	<u>6,615</u>
Current Liabilities		
Trade payables	1,204	1,999
Other payable & accruals	2,024	798
Amount due to directors	-	11
Contract Liabilities	583	522
Term Loan	B7 439	299
Lease liabilities	B7 252	321
	<u>4,502</u>	<u>3,950</u>
Total liabilities	<u>10,709</u>	<u>10,565</u>
TOTAL EQUITY AND LIABILITIES	<u>83,281</u>	<u>49,401</u>
Number of ordinary shares in issue ('000)	367,141	306,455
Net assets value per share (RM)	<u>0.1939</u>	<u>0.1228</u>

(The unaudited Condensed Consolidated Balance Sheet should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 DEC 2020
(The figures have not been audited)

	12 months Ended 31 Dec 2020 (Unaudited) RM'000	12 months Ended 31 Dec 2019 (Audited) RM'000
CASHFLOWS FROM OPERATING ACTIVITIES		
Profit/(loss) before taxation	(522)	(660)
Adjustment for :		
Depreciation of property, plant and equipment	644	694
Depreciation of right-of-use assets	692	367
Amortisation of intangible assets	14	35
Unrealised loss/(gain) on foreign exchange	7	32
Net impairment losses/(reversal of) on contract assets	-	61
Gain on disposal of short term investment	(15)	(392)
Net impairment losses on other receivables	-	165
Dividend income from short term investments	(250)	(111)
Interest income	(212)	(229)
Deposits written off	-	502
Net impairment losses on amount due from an associate	-	230
Net (reversal of)/impairment losses on trade receivables	380	(138)
Written off of property, plant & equipment	57	-
Net (reversal of)/addition interest expense on ROU	(165)	-
Interest expense - others	112	340
Net loss/(gain) on changes in fair value of short term in	(26)	235
Loss on disposal of property, plant and equipment	3	-
Share of loss/ (profit) in an associate	43	102
Employees Share Option Expense	339	-
Operating profit/(loss) before working capital changes	<u>1,101</u>	<u>1,233</u>
Working capital changes :		
(Increase)/ Decrease in inventories	(153)	(424)
(Increase)/ Decrease in contract assets	914	(2,132)
(Increase)/ Decrease in trade and other receivables	2,425	(1,520)
(Increase)/ Decrease in amount due from associate	(7,069)	507
Increase in contract liabilities	60	12
(Decrease)/ Increase in trade and other payables	<u>(514)</u>	<u>(221)</u>
Cash (used in)/generated from operating activities	(3,236)	(2,545)
Interest paid	(112)	(340)
Tax refunded	-	769
Tax paid	<u>(243)</u>	<u>(509)</u>
Net cash (used in)/generated from operating activities	<u>(3,591)</u>	<u>(2,625)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Net (placements)/withdrawal of short term investments	(29,084)	2,471
Net placement of deposits under lien	(227)	(223)
Interest received	212	230
Acquisition of additional shares in a subsidiary from non-cont	-	(45)
Purchase of property, plant and equipment	(93)	(436)
Acquisition of additional shares in a subsidiary by non-control	50	-
Net cash (used in)/generated from investing activities	<u>(29,142)</u>	<u>1,997</u>
CASHFLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of shares	34,496	-
Share Application Money	933	-
Net repayment to directors	-	(30)
Proceeds from term loan	(219)	517
Repayments of principal portion of lease liabilities	(635)	(276)
Purchase of treasury share	(66)	(13)
Net cash generated from financing activities	<u>34,509</u>	<u>198</u>
Net Increase/(decrease) in cash and cash equivalents	1,776	(430)
Currency translation difference	-	(24)
Cash and cash equivalents at beginning period	9,133	9,587
Cash and cash equivalents at end of period	<u>10,909</u>	<u>9,133</u>
Cash and cash equivalents as at 31 Dec 2020 and 31 Dec 2019 comprise the following :		
	2020	2019
	RM'000	RM'000
Fixed deposits with licensed banks	7,731	7,503
Cash and bank balances	<u>10,909</u>	<u>9,133</u>
Deposit, cash and bank balances	18,640	16,636
Less: Fixed deposits with licensed banks (pledged with bank	<u>(7,731)</u>	<u>7,503</u>
Cash and cash equivalents	<u>10,909</u>	<u>9,133</u>

(The unaudited Condensed Consolidated Cashflow Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DECEMBER 2020
 (The figures have not been audited)

	Attributable to Equity Holders of the SGB						
	<-----Non-distributable----->			Distributable			
	Share Capital RM'000	Option Reserve RM'000	Treasury Shares RM'000	Retained Earnings RM'000	Total RM'000	Non-controlling Interests RM'000	Total RM'000
As at 1 January 2019 (audited)	31,089	212	-	7,238	38,539	1,111	39,650
Loss for the financial year and total comprehensive loss for the financial year	-	-	-	(890)	(890)	134	(756)
Purchase of treasury shares			(13)		(13)		(13)
Disposal of equity interest in a subsidiary				3	3	(3)	-
Acquisition of additional interest in a subsidiary from minority interest				-	-	(45)	(45)
At 31 Dec 2019 (audited)	31,089	212	(13)	6,351	37,639	1,197	38,836
As at 1 January 2020 (audited)	31,089	212	(13)	6,351	37,639	1,197	38,836
Issuance of ordinary shares pursuant to:-							
- Exercise of ESOS	552				552		552
- Private placement	28,265				28,265		28,265
- Exercise of Warrants	5,401				5,401		5,401
ESOS Option Reserve		339			339		339
Transferred to share capital upon exercise of ESOS	278	(278)			-		-
ESOS forfeited		(25)		25	-		-
Loss for the financial year and total comprehensive loss for the financial year	-	-	-	(943)	(943)	138	(805)
Arising from additional investment in subsidiaries						50	50
Purchase of treasury shares	-	-	(66)	-	(66)	-	(66)
At 31 Dec 2020 (unaudited)	65,585	248	(79)	5,433	71,187	1,385	72,572

¹ Effective from 31st January 2017, the new Companies Act 2016 ("the Act") abolished the concept of authorised share capital and par value of share capital. Consequently, the credit balance of the share premium becomes part of the Company's share capital pursuant to the transitional provision set out in Section 618(2) of the Act. Notwithstanding this provision, the Company may within 24 months from the commencement of the Act, use this amount for purpose set out in Section 618 (3) of the Act. There is no impact on the number of ordinary shares in issue or the relative entitlement of any members as a result of this transition.

(The unaudited Condensed Consolidated Changes In Equity should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 31 DECEMBER 2020

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The interim financial report of the Company and its subsidiaries ("Group") is unaudited and is prepared in accordance with MFRS 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market and should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2019.

A2. Changes in accounting policies

The accounting policies adopted by the Group in the interim financial report are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2019. During the financial period, the Group has adopted the following standards, amendments and IC Interpretations issued by the Malaysian Accounting Standards Board ("MASB"), which became effective for annual period beginning on or after 1 January 2020.

MFRSs/ Amendments/ Interpretations

Amendments to MFRS 3, Business Combinations (Definition of a Business)
Amendments to MFRS 7, Financial Instruments (Disclosure - Interest Rate Benchmark Reform)
Amendments to MFRS 9, Financial Instruments
Amendments to MFRS 101, Presentation of Financial Statements (Definition of Material)
Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors (Definition of Material)
Amendments to MFRS 139, Financial Instruments (Recognition and Measurement)

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 Jun 2020
Amendments to MFRS 16, Leases – Covid-19-Related Rent Concessions

The adoption of the above did not have any significant impact on the financial statements of the Group.

The Group have not applied the following standards and amendments that have been issued by the MASB which are not yet effective:

Effective for annual periods beginning on or after 1 January 2021

MFRS 17, Insurance Contracts

Effective for annual periods beginning on or after a date to be determined by MASB

Amendments to MFRS 10 and MFRS 128 - Sale or Contribution of Assets between an Investor and its Associates or Joint Ventures

A3. Auditors' report on preceeding annual financial statements

The auditors' report on the financial statements for the financial year ended 31 December 2019 was not subject to any qualification.

A4. Seasonality or cyclicity factors

The Group's operations were not affected by seasonal or cyclical changes.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items or events affecting assets, liabilities, equity, net income or cash flows of the Group during the quarter under review.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect in the current quarter results.

A7. Debts and equity securities

There were no other issuance, cancellation, resale, repurchase and repayment of debt and equity securities.

A8. Dividends Paid

There was no dividend paid during the quarter under review.

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING (CONTD.)

A9. Segmental information

During the financial period, the Group revenue was contributed mainly from the following business segments:

- i) Engineering Equipment Design and development of equipment and software for engineering education, research and technical and vocational training ("TVET") in chemical, mechanical, electrical, civil and control engineering under SOLTEQ brand, including metal
- ii) Industrial Fabrication and Assembly Metal fabrication and assembly works.
- iii) Industrial Automation Provision of industrial automation solutions, currently specialising in water works such as remote monitoring system for dams, tidal control system for irrigation and automation system for flood mitigation under SOLWEB brand.
- iv) Solar Business Promoting all types of businesses relating to green and renewal energy.
- v) Biotechnology Undertakes all types and kinds of biotechnology business.
- vi) Industrial Lubricants Production and distribution of industrial lubricants under SOLMAX brand and OEM brand.

Segmental financial information for 12 months period ended 31 Dec 2020 and 31 Dec 2019 are as follows:

	2020								
	Engineering Equipment RM'000	Industrial Fabrication and Assembly RM'000	Industrial Automation RM'000	Industrial Lubricants RM'000	Biotechnology RM'000	Solar Business RM'000	Others RM'000	Elimination RM'000	Total RM'000
Segment revenue									
External	10,004	2,975	3,413	1,190	126	250	117	0	18,075
Inter-segment	5	795	99	11	-	-	-	(910)	-
Total revenue	10,009	3,770	3,512	1,201	126	250	117	(910)	18,075

Results

Segment results	620	228	725	(39)	(165)	(45)	(1,856)		(532)
Share of loss in an associate									(43)
Interest expense									53
Loss before taxation ("LBT")									(522)
Income tax expense									(283)
Loss after taxation ("LAT")									(805)
Non-controlling Interest									(138)
Profit attributable to equity holders of the company									(943)

	2019								
	Engineering Equipment RM'000	Industrial Fabrication and Assembly RM'000	Industrial Automation RM'000	Industrial Lubricants RM'000	Biotechnology RM'000	Solar Business RM'000	Others RM'000	Elimination RM'000	Total RM'000
Segment revenue									
External	9,180	3,930	3,624	1,539	368	204	4	-	18,849
Inter-segment	174	900	94	3	-	-	-	(1,171)	-
Total revenue	9,354	4,830	3,718	1,542	368	204	4	(1,171)	18,849

Results

Segment results	911	488	376	(39)	(74)	(5)	(1,875)		(218)
Share of loss in an associate									(102)
Interest expense									(340)
Loss before taxation ("LBT")									(660)
Income tax expense									(96)
Loss after taxation ("LAT")									(756)
Non-controlling Interest									(134)
Profit attributable to equity holders of the company									(890)

A10. Valuation of property, plant and equipment

The Group did not revalue any of its property, plant and equipment during the quarter under review.

A11. Material events subsequent to the end of the quarter

There were no material events occurring subsequent to the end of the reporting period to the date of announcement except for the event as disclosed in item A12.

A12. Changes in the composition of the Group

There were no changes in the composition of the Group for the quarter under review.

A13. Contingent liabilities

There were no material contingent liabilities as at the date of this announcement.

A14. Capital commitment

There were no material capital commitment as at the date of this announcement.

A15. Significant Related Party Transaction

Year-to-date
31 Dec 2020
RM'000

Income

Sales to an associate

7,205

The Group had obtained the shareholders' mandate to enter into recurrent related party transactions of a revenue or trading nature at Sixteenth Annual General Meeting of the Company.

**B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
 LISTING REQUIREMENTS FOR THE ACE MARKET**

B1. Review of Performance

Comparison with corresponding quarter in previous financial year

The Group recorded a revenue of RM5.87 million during the quarter, an increase of RM0.75 million as compared to the revenue of RM5.12 million in the corresponding quarter in previous financial year. The increase in revenue was mainly attributable to more projects progress had been made during the quarter.

For the quarter ended 31 December 2020, the Group recorded a loss after tax ("LAT") of RM1.13 million against LAT of RM0.79 million reported in the preceding year quarter ended 31 December 2019. The higher loss during the quarter was mainly attributable to lower projects gross profit compared to corresponding quarter in previous year..

B2. Comparison with Preceding Quarter's Results

The Group's revenue for the quarter under review was RM5.87 million, an increase of RM0.59 million, as compared to the revenue of RM5.29 million registered in the preceding quarter. The increase is due to more projects progress had been made during the quarter.

The Group reported a loss of RM1.13 million during the quarter, as compared to the profit of RM0.58 million in the preceding quarter. The loss reported in this quarter was mainly attributed to the lower gross profit, provision of impairment and private placement fees.

B3. Prospects for this financial year ending 31 December 2021

The COVID-19 pandemic had significantly affected the Malaysian and global economies. Although companies are allowed to operate with SOP to prevent the virus from spreading, the recovery of the economy is slow.

On 23 September 2020, the Group has entered into a Registration, Manufacturing and Commercialisation Agreement ("the Agreement") with CanSino Biologics Inc ("CanSinoBIO") to do the fill and finish, marketing and distribution for COVID-19 vaccine in Malaysia. The COVID-19 vaccine, Ad5-nCoV is jointly developed by CanSinoBIO and Beijing Institute of Biotechnology, Academy of Military Medical Sciences.

Subsequent to the above, on 30 October 2020, the Group has received a Letter of Authorisation ("LOA") from CanSinoBIO to develop the business in Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos and Brunei for the marketing and distribution of COVID-19 vaccine.

The Board believes that the supply of vaccines and biologics possesses the potential to contribute positively to future earnings and the financial position of SGB Group due to biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare.

With the collaboration with CanSinoBIO, the Board is optimistic with the Group's future growth.

B4. Profit guarantee

The Group has not issued any profit forecast nor guarantee in respect of any corporate proposal.

B5. Taxation

	Quarter ended		Year-to-date	
	31 Dec 2020	31 Dec 2019	31 Dec 2020	31 Dec 2019
	RM'000	RM'000	RM'000	RM'000
Current taxation				
-Provision for taxation	228	170	228	170
- Under/(Over) provision in prior years	55	(74)	55	(74)
Deferred taxation	-	-	-	-
	<u>283</u>	<u>96</u>	<u>283</u>	<u>96</u>

B6. Profit on sale of unquoted investments and/or properties

There were no disposal of unquoted investment and/or properties for the quarter under review.

B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD LISTING REQUIREMENTS FOR THE ACE MARKET (CONTD.)

B7. Group borrowings and debt securities

Details of the Group's borrowings as at 31 Dec 2020 are as follows :

	Current RM'000	Non-current RM'000	Total RM'000
Secured :			
Hire purchase (included in lease liabilities)	252	292	544
Term loan	439	5,915	6,354
Total	691	6,207	6,898

B8. Status of Corporate Proposals

A) Update on Employees' Share Option Scheme (ESOS) as at 31 Dec 2020

The Company had obtained its shareholders approval for the establishment of the ESOS of up to 30% of the total issued and paid-up share capital for the eligible employees and directors and its subsidiaries at the EGM dated 16 January 2014.

Below show the details of the shares that had been granted and exercised under the ESOS as at 31 Dec 2020:

ESOS Option Grant Date	Expiry Date	Exercise Price	No. of Share			Status
			Granted	Exercised and Listed	Lapsed	
22 July 2014	29 Jan 2019	RM0.135	11,134,000	11,103,000	31,000	Completed
8 January 2015	29 Jan 2019	RM0.185	6,000,000	6,000,000	-	Completed
28 September 2016	29 Jan 2024	RM0.220	6,000,000	3,823,000	422,000	Ongoing
8 August 2020	29 Jan 2024	RM0.175	2,605,000	1,741,000		Ongoing

On 22 January 2019, the Company had announced to extend the existing ESOS of the Company which commenced on 30 January 2014 and expired on 29 January 2019 for another five (5) years until 29 January 2024 in accordance with the terms of the ESOS

B) Proposed Renewal of Authority for the Company to Purchase Its Own Shares

The Renewal of Authority for Share Buy Back had been approved by shareholders at the sixteenth Annual General Meeting of the Company. As at todate, the total number of treasury shares is 1,462,700, there is no any changes during the quarter.

C) Private Placement of Up To 10% of the Total Issued Shares of SGB

On 9 December 2020, on behalf of the Board, M&A Securities had announced that the Private Placement had been completed following the listing of and quotation for 30,857,600 Placement Shares on the ACE Market of Bursa Securities on 9 December 2020.

D) Proposed Diversification of the Existing Business of SGB and its Subsidiaries to Include the Pharmaceutical Related Business ("Proposed Diversification")

On 15 January 2021, the Company had announced that the Proposed Diversification had been approved by its shareholders during the Extraordinary General Meeting on 15 January 2021.

B9. Realised/ Unrealised Profits

	As at 31 Dec 2020 RM'000
Total retained earnings of the Company and its subsidiaries	
- realised	14,189
- unrealised	20
	14,209
Total share of accumulated loss of an associate	
- realised	(230)
- unrealised	-
	13,979
Less: Consolidated adjustments	(8,546)
Retained profit as per financial statement	5,433

**B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
LISTING REQUIREMENTS FOR THE ACE MARKET (CONTD.)**

B10. Profit Before Tax

	Quarter ended 31 Dec 2020 RM'000	Quarter ended 31 Dec 2019 RM'000
Profit before tax is derived after charging:		
Depreciation of PPE & ROU	272	557
Amortisation of intangible asset	10	9
Impairment loss on other receivables	-	165
Impairment on trade receivables and contract asset	35	57
Interest expense	58	271
Loss on foreign exchange:		
-Realised	46	3
-Unrealised	7	24
PPE written off	<u>35</u>	<u>-</u>
and crediting:		
Interest income	(66)	(70)
Gain on disposal of short term investment	-	(69)
Gain on disposal of PPE	(10)	-
Gain on foreign exchange:		
-Unrealised	<u>-</u>	<u>-</u>

B11. Off balance sheet financial instruments

There were no financial instruments with off-balance sheet risk as at the date of this announcement applicable to the Group.

B12. Dividends

The Board of Directors did not recommend any payment of dividend in respect of the quarter under review.

B13. Earnings per share

	Current Quarter ended 31 Dec 2020	Comparative Quarter ended 31 Dec 2019	Current year to date ended 31 Dec 2020	Preceding year to date ended 31 Dec 2019
Net profit/(loss) for the period attributable to equity holders (RM'000)	(1,026)	(788)	(943)	(890)
Basic				
Weighted average number of ordinary shares in issue ('000)	367,141	306,455	367,141	306,455
Basic EPS (sen)	<u>(0.279)</u>	<u>(0.257)</u>	<u>(0.257)</u>	<u>(0.290)</u>
Diluted				
Weighted average number of ordinary shares in issue ('000)	367,141	306,455	367,141	306,455
Effect of dilution: share options and convertible warrants ('000)	79,509	-	79,509	-
Adjusted weighted average number of ordinary shares in issue and issuable ('000)	446,650	306,455	446,650	306,455
Diluted EPS (sen)	<u>(0.230)</u>	<u>(0.257)</u>	<u>(0.211)</u>	<u>(0.290)</u>

**BY ORDER OF THE BOARD
SOLUTION GROUP BERHAD**